EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
CorMedix Inc.
CRMD

CRMD CorMedix Inc.

CorMedix Inc. · NASDAQ
Market Open
7.72
▼ ⁦-0.90%⁩ (-0.07)
Market Cap$605.6M
Beta1.50
52w Low52w High
6.1314.66
Last Week
⁦-3.02%⁩
Last Month
⁦+0.65%⁩
Last 3 Months
⁦-6.20%⁩
Last Year
⁦-47.27%⁩
EL7 Factor Analysis
How we score this
Overall90
Excellent — top fifth of the marketContrarianF 5/9Better than 90% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
83
3.5x▲17.6xTop tier
▸
Growth
86
280.5%▲7.1%Top tier
▸
Quality
97
48.4%▲4.5%Top tier
▸
Safety
85
—2.6xTop tier
▸
Capital Return
11
—2.15%Bottom tier
▸
Momentum
32
-47.6%▼2.3%Bottom tier
▸
Sentiment
69
4▲3Top tier

Frequently Asked Questions

What is CorMedix Inc. stock?▼

CorMedix Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in CorMedix Inc.?▼

You can buy CorMedix Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating CorMedix Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does CorMedix Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in CorMedix Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

Fair Value
Low confidenceCurrent price$7.72
Analyst target · 3 analysts
$14
⁦+81%⁩
See it clearly undervalued
Range ⁦$14–$14⁩
vs
DCF (estimate)
$35
⁦+352%⁩
Sees it clearly undervalued
⁦11.0⁩% discount · ⁦0⁩% growth
Bottom lineThe two methods broadly agree — estimate range ⁦$14–$35⁩.

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener

AI analysis from the earnings call, financials and news

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 3 analysts setting price target
$14.00
⁦+81.3%⁩
Current Price $7.72·Median $14.00
Low
$14.00
High
$14.00
Street summary

Slight Increase in Target Amid Firm Consensus

Bullish tilt

CorMedix’s consensus price target rose to 14 from 13.5, an increase of 0.5 or 3.7% over one day, seven days, and 30 days, while the number of analysts remained at three. The highest, lowest, and average targets are all at 14, indicating no apparent divergence among current estimates; the target is equivalent to approximately 66.1% above the current price of 8.43.

As of 2026-09-07
Revisions momentum · 30d
⁦+3.7%⁩
Average rating
★ 4.60
Strong Buy
Analyst coverage
5
Buy conviction
100%
High
Target dispersion
0%
Analyst ratings over time5 analysts rating
3
2
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months4.43 → 4.60
Recent analyst moves
  • = Reiterate2026-04-28
    RBC Capital
    Outperform· $14.00
  • = Reiterate2026-03-06
    Leerink Partners
    Outperform· $13.00
  • = Reiterate2026-01-23
    H.C. Wainwright
    —· $13.00
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    3.51x
    3.68x44.95x
    Very cheap
  • Forward P/E
    1930.00x
    4.70x37.61x
    Very expensive
  • EV / EBITDA
    2.37x
    3.78x30.25x
    Very cheap
  • FCF Yield
    35.1%
    -145.2%7.8%
    Exceptional
  • Revenue Growth YoY
    280.5%
    -57.4%93.8%
    Exceptional
  • EPS Growth YoY
    182.1%
    -159.3%129.8%
    Exceptional
  • Gross Margin
    82.8%
    12.8%90.7%
    Strong
  • ROIC
    48.4%
    -154.2%16.1%
    Exceptional
  • Net Debt / EBITDA
    —
    —
  • Dividend Yield
    —
    —
  • Payout Ratio
    —
    —
  • Altman Z-Score
    —
    —
Financial Analysis
|